Display Settings:

Format

Send to:

Choose Destination

    Br J Ophthalmol. 2001 Jun;85(6):686-8.

    Long term results and complications of trabeculectomy augmented with low dose mitomycin C in patients at risk for filtration failure.

    Casson R, Rahman R, Salmon JF.

    Oxford Eye Hospital, Woodstock Road, Oxford OX2 6HE, UK.

    AIM: To determine the results and complications up to 5 years after trabeculectomy with 0.02% mitomycin C (MMC) in glaucoma patients at risk for failure of filtration surgery. METHODS: A consecutive series of 21 eyes from 20 patients who underwent trabeculectomy with MMC 0.02%, with an exposure time of 2 minutes, was retrospectively analysed and the results were compared with previously published data. RESULTS: The mean preoperative intraocular pressure (IOP) was 28 mm Hg on an average of 2.8 glaucoma medications, and the mean postoperative IOP after 3 years was 14 mm Hg on an average of 0.4 medications. Three years after trabeculectomy, 17 of 21 (80.9%) eyes had an IOP of less than 21 mm Hg without medical treatment. Using Kaplan-Meier life table analysis the 5 year probability of an IOP less than 21 mm Hg without medication was 67% and with medication was 90%. Two patients required further glaucoma surgery during the first postoperative year, and another developed hypotonous maculopathy which was reversed after bleb revision. Seven patients developed visually significant cataract as a late consequence of the surgery. There were no bleb related infections. CONCLUSION: In the long term MMC 0.02% used for 2 minutes intraoperatively is an effective adjunctive treatment in glaucoma patients at risk for bleb failure and in this dose is associated with few complications.

    PMID: 11371489 [PubMed - indexed for MEDLINE]

    PMCID: 1724022

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Mitomycin (Mutamycin®)

      Your doctor has ordered the drug mitomycin to help treat your illness. The drug is given by injection into a vein.